This is the authors' abstract. We don't add key points for this paper.
At the present randomized controlled parallel clinical trial, effects of 500 mg curcumin supplementation along with a weight-loss diet (500 kcal reduction from the daily requirements) for eight weeks has been studied on the gut dominant phylum and butyrate-producing bacteria in people with obesity (BMI ≥ 30 kg/m 2 ) who metabolically were health. A significant difference was observed in Bacteroidetes ( p = 0.01), Actinobacteria ( p = 0.001), and Proteobacteria ( p = 0.003) population between the two studied groups at the end. Bacteroidetes significantly increased in the curcumin ( p = 0.04), however Actinobacteria significantly decreased in the placebo ( p = 0.02) group from baseline up to the end. The population of Fecalibacterium prausnitzii was significantly different between the two groups at the end ( p = 0.004). Relative abundance of Fecalibacterium prausnitzii significantly decreased in the placebo group ( p = 0.03). A significant effect of curcumin has been observed on the population of Fecalibacterium prausnitzii (β = 0.26, 95 %CI = 0.23–7.7, p = 0.03). Curcumin supplementation in healthy obese people increased butyrogenic bacteria and prevented decrease in Actinobacteria, as phylum containing probiotic bacteria. More clinical trials are needed to reach a concise result. The present study registered under ClinicalTrials.gov Identifier No. IRCT20240209060948N1. • Curcumin along with weight loss diet increased the gut butyrogenic bacteria. • The most effect of curcumin has been observed on the Fecalibacterium prausnitzii. • Curcumin prevented weight loss diet-induced reduction in Actinobacteria population. • Beneficial effects on the bacterial gut has been observed regardless of weight loss.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mousavi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: